Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
Phase 3positiveSYCUME®Positive
AI Analysis
Summary
Innovent Biologics announced that its Phase 3 RESTORE-3 study of SYCUME® (Teprotumumab N01 Injection) met its primary endpoint in patients with inactive thyroid eye disease, demonstrating significant proptosis improvement with a 60.4% response rate and favorable safety profile.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Primary endpoint met with 60.4% response rate for proptosis improvement (LS Mean Change from Baseline -1.88 mm) and favorable safety profile
Importance:8/10
Sentiment:
0.85
Phase 3 SuccessThyroid Eye DiseaseTeprotumumabProptosisClinical TrialPrimary Endpoint Met
Related Companies
Read the original article
Published by PR Newswire Biotech on October 9, 2026 12:00 AM